Cann Group (CAN.AX) Aktie Kurs
Cann Group Kurs
Intäkterna har vuxit med 79,5 % per år under de senaste 11 åren till 8,56 M AUD. Cann Groups nettovinstmarginal ligger på 237,1 %, upp från −412,9 % för några år sedan.
Cann Group aktiekurs
Hämta dessa data via Eulerpool API
100 000 anrop/mån gratis · inget kreditkort
Cann Group affärsmodell och aktieanalys
Vanliga frågor om Cann Group-aktien
Cann Group Ltd is an Australian company that operates in the medicinal cannabis industry. Its business model revolves around cultivation, manufacturing, and distribution of pharmaceutical-grade cannabis products and providing services to the medicinal cannabis sector. With a focus on research and development, Cann Group aims to support healthcare professionals and patients by developing high-quality therapeutic products derived from cannabis plants. The company's expertise lies in the production of standardized cannabis cultivars, extraction, and development of new formulations to meet the evolving needs of the medical industry. Cann Group Ltd strives to establish itself as a leading player in the medicinal cannabis market.
Cann Group Ltd is primarily active in the cannabis industry.
The main competitors of Cann Group Ltd in the market include other companies involved in the production and distribution of medical cannabis and cannabis-related products. Some significant competitors of Cann Group Ltd may include AusCann Group Holdings Ltd, Althea Group Holdings Ltd, and Little Green Pharma Ltd. These companies operate in the same industry and focus on the cultivation, manufacturing, and sale of medical cannabis products. Cann Group Ltd competes with these companies to gain market share, secure partnerships, and expand their customer base in the rapidly growing cannabis industry.
Cann Group Ltd is an Australian company that specializes in cultivating and producing medical cannabis. Established in 2014, Cann Group was the first to be granted a license to cultivate and research cannabis for medicinal purposes in Australia. With a strong commitment to quality and compliance, the company has built state-of-the-art facilities and established strategic partnerships to expand its operations. Cann Group is dedicated to providing safe and effective cannabis-based products to improve patient outcomes and is at the forefront of the rapidly growing medicinal cannabis industry in Australia.
Cann Group Ltd has achieved several significant milestones in its operations. Firstly, the company became the first Australian business to obtain a license to cultivate medicinal cannabis for research purposes in 2017. This achievement positioned Cann Group Ltd as a pioneer in the country's emerging medicinal cannabis industry. Additionally, the company successfully completed its first commercial cannabis harvest in 2018, marking another important milestone. Furthermore, Cann Group Ltd obtained its crucial Manufacture License in 2019, allowing the company to produce and distribute medicinal cannabis products in Australia. These milestones highlight Cann Group Ltd's commitment to advancing the availability and quality of medicinal cannabis within the country's market.
Cann Group Ltd is primarily present in Australia.
Cann Group Ltd, a leading Australian medicinal cannabis company, embodies a strong set of values and corporate philosophy. The company is committed to producing high-quality medical cannabis products to improve the lives of patients. Cann Group values innovation and sustainability, constantly seeking new ways to enhance their cultivation and manufacturing processes. With a focus on research and development, they aim to continually expand their product offerings and provide effective and safe treatments. Cann Group Ltd prides itself on its dedication to investors, transparency, and regulatory compliance, ensuring a trustworthy and reliable approach to business.
5 analytiker betygsätter för närvarande Cann Group-aktien: 4 rekommenderar köp, 1 behåll och 0 sälj.
Omräknat till aktuell växelkurs handlas Cann Group-aktien till 0,00 EUR (0,00 AUD).
Cann Group-aktien (CAN.AX) är noterad på 3 börser, bland annat: ASX (CAN.AX), Frankfurt (CVJ.F).
Cann Group Ltd is an Australian company specializing in the medical cannabis market. Its business model involves producing, developing, and distributing cannabis for medical use. The company serves various segments, such as the market for human medical products, the veterinary sector, and the recreational and wellness sector. The company is well positioned to benefit from the growing demand for medical cannabis, CBD products for pets, and recreational products.
Omsättningen för Cann Group är 8,56 M AUD. Denna siffra baseras på aktuella finansiella data och återspeglar företagets affärsresultat.
Nettovinsterna för Cann Group är 20,30 M AUD. Nettovinsterna återspeglar företagets lönsamhet efter avdrag för alla utgifter.
Kurs-vinstkvoten (P/E) för Cann Group är för närvarande 0,30. P/E-talet jämför den aktuella aktiekursen med vinsten per aktie och hjälper investerare att bedöma värderingen av Cann Group-aktien.
Kurs-försäljningskvoten (P/S) för Cann Group är för närvarande 0,71. P/S-talet jämför börsvärdet med den årliga omsättningen och fungerar som ett värderingsmått för Cann Group-aktien.
Eulerpool Quality Score för Cann Group är 5/10.
ISIN för Cann Group är AU000000CAN2. ISIN (International Securities Identification Number) är en globalt unik identifierare för värdepapper.
WKN för Cann Group är A2DSUQ. WKN (Wertpapierkennnummer) är ett sexsiffrigt tyskt identifieringsnummer för värdepapper.
Tickern för Cann Group är CAN.AX. Tickersymbolen används för att handla Cann Group-aktier på börsen.
Cann Group aktie
Cann Group Jämförbar grupp
Cann Group Ticker
Cann Group FIGI
Alla nyckeltal och djupgående analys av Cann Group
Vår aktieanalys av Cann Group-aktien innehåller viktiga finansiella nyckeltal som omsättning, vinst, P/E-tal, P/S-tal, EBIT samt information om utdelningen. Dessutom granskar vi aspekter såsom aktier, börsvärde, skulder, eget kapital och skuldförbindelser hos Cann Group. Om du söker mer detaljerad information om dessa ämnen erbjuder vi på våra undersidor ingående analyser: